You are viewing the site in preview mode

Skip to main content

Table 2 Comparison between the PTEN gene and protein evaluation methods for clinical endpoints of the HCRP cohort

From: PTEN loss in Gleason grade 7 prostate tumors exhibits intratumoral heterogeneity and is associated with unfavorable pathological features

  FISH (n = 41) IHC (n = 39)
Homo Hemi Intact P Loss Intact P
Age 62 66 62 0.50 62 62.5 0.77
Time to Biochemical Recurrencea 45 87 83.5 0.37 82 84 0.52
Preoperative PSA 15.5 12.4 7.08 0.47 10.9 7.57 0.46
Gleason Score
 3 + 4 2 1 30 0.001* 5 28 0.29
 4 + 3 1 4 3 2 4
Pathological Stage
 2 1 5 27 0.09 4 28 0.08
 3 2 0 6 3 4
Positive Surgical Margins
 No 0 4 23 0.04* 3 22 0.66
 Yes 3 1 10 4 10
Perineural Invasion
 No 2 1 12 0.42 5 10 0.08
 Yes 1 4 21 2 22
Extraprostatic Extension
 No 1 5 27 0.09 4 28 0.08
 Yes 2 0 6 3 4
Vesicle Invasion
 No 2 5 30 0.32 6 30 0.45
 Yes 1 0 3 1 2
Biochemical Recurrencea
 No 2 4 25 0.76 5 26 0.24
 Yes 1 1 5 2 3
Gleason Score Upgrade
 No 1 2 15 0.02* 2 16 0.40
 3 + 4 1 0 15 3 12
 4 + 3 1 3 3 2 4
  1. Median per group for time to biochemical recurrence is shown in months. Median of preoperative PSA levels are shown in ng/mL. Median of age at surgery is indicated in years. Kruskal-Wallis test was used to compare continuous variables for FISH data and Mann-Whitney test for IHC data. Categorical variables were compared through Fisher’s exact test. *P < 0.05. aData available for 40 patients. FISH fluorescence in situ hybridization, IHC immunohistochemistry, Homo Homozygous deletion, Hemi Hemizygous deletion
\